Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Technology Journal of Ohio.
Press releases published on September 2, 2025
Nkarta to Participate in a September Investor Conference
GlobeNewswire
·
September 2, 2025
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor …
OSS Announces Upcoming Investor Events
GlobeNewswire
·
September 2, 2025
ESCONDIDO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- One Stop Systems, Inc. (OSS or the Company) (Nasdaq: OSS), a leading provider of rugged, enterprise-class compute solutions for AI, machine learning (ML), and sensor processing at the edge, today …
Step Pharma announces first participant dosed in a phase 1b clinical trial of dencatistat for essential thrombocythaemia
GlobeNewswire
·
September 2, 2025
Start of the phase 1b trial in a new indication expands Step Pharma’s clinical programme, building on the development of dencatistat in lymphoma and solid tumours This milestone marks the third indication for dencatistat, a first-in-class, highly selective …
Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 2, 2025
BASKING RIDGE, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other …
Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 2, 2025
SALT LAKE CITY, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the …
Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 2, 2025
WATERTOWN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to …
Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
GlobeNewswire
·
September 2, 2025
SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today …
PDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 2, 2025
PRINCETON, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced …
Department of Defense (DoD) Awards Nearly $1 Million to Steadman Philippon Research Institute (SPRI) for Breakthrough Study on Extracellular Vesicles Therapeutic for Joint Regeneration
GlobeNewswire
·
September 2, 2025
VAIL, Colorado / BASALT, Colorado, Sept. 02, 2025 (GLOBE NEWSWIRE) -- The U.S. Department of Defense (DoD) has awarded a $962,977 contract to Steadman Philippon Research Institute (SPRI) to launch a year-long clinical study focused on improving therapies …
KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director
GlobeNewswire
·
September 2, 2025
ARLINGTON, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, …
Vielight Neuro Technology Gains Traction Across Professional Sports, Powering Champions with Evidence-Backed Results
GlobeNewswire
·
September 2, 2025
Toronto, Ontario, Sept. 02, 2025 (GLOBE NEWSWIRE) -- TORONTO — Aug. 28, 2025 — Vielight, the pioneers of brain photobiomodulation (PBM) neurotechnology, is rapidly emerging as a game-changer for elite athletes. NFL and NCAA football players, Olympic …
Avaap Introduces New Program to Make it Easier for Emerging Higher Education and Government Organizations to Deploy Workday
GlobeNewswire
·
September 2, 2025
COLUMBUS, Ohio, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Avaap, a recognized leader in digital transformation for higher education, government, and nonprofit sectors, today announced the launch of Avaap One, an innovative deployment program designed to make it …
Nasus Pharma Announces Upcoming Presentation at H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 2, 2025
TEL AVIV, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical …
Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel
GlobeNewswire
·
September 2, 2025
CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Adi Osovsky, S.J.D. as General Counsel. Dr. Osovsky …
Opus Genetics Appoints Rob Gagnon as Chief Financial Officer
GlobeNewswire
·
September 2, 2025
RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic …
Calidi Biotherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 2, 2025
SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic …
4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness
GlobeNewswire
·
September 2, 2025
Julie Clark, M.D., promoted to Chief Medical Officer Liansheng Zhu, Ph.D., joined as SVP, Biometrics and Data Quality 4FRONT-1 Phase 3 trial enrollment continues to exceed expectations, with enrollment completion now expected in Q1 2026 Addition of …
electroCore to Participate at H.C. Wainwright Global Investment Conference
GlobeNewswire
·
September 2, 2025
ROCKAWAY, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the H.C. Wainwright 27th Annual Global Investment …
Krystal Biotech to Present at Cantor Global Healthcare Conference 2025
GlobeNewswire
·
September 2, 2025
PITTSBURGH, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the Cantor Global Healthcare Conference 2025 on September 4, 2025, in New York. Krish S. Krishnan, …
First Set of 1-Year Clinical Results from RESOLVE Trial in Eosinophilic Esophagitis (EoE), Durable and Sustained Symptom & Tissue Responses after Dosing with EP-104GI
GlobeNewswire
·
September 2, 2025
At 12 months, 2/3rds of Cohort 5 patients (48mg dose, 4mg per site) remained in clinical remission after their treatment with EP-104GI All Cohorts followed to 9 months have maintained clinically meaningful improvements in tissue health as measured by EoE …